Foreign Funds Enter Nationwide Hospital Operation And Management
This article was originally published in PharmAsia News
Hong Kong-listed Golden Meditech has paid HK$830 million to purchase 70 percent of Daopei, China's largest blood disease specialist hospital. At the same time, the firm will gain business licenses and knowledge for national hospital operation and management through its 60 percent acquisition of Jianliang Hospital Management Co., which is the first foreign-owned enterprise qualified to run hospitals nationwide. The deal marks the entry of foreign funds into the sector. The acquisition will allow Golden Meditech to form a complete health care chain and optimize its business network in China's interior region. It will also bring synergy to its health care service, umbilical cord blood hematopoietic stem cell storage and application, as well as medical equipment production and sales. (Click here for more - Chinese Language)
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?